FY02 was indeed a year of all round performance for Dr. Reddy's. The company took major strides on all fronts viz, research, international breakthroughs, in-organic growth and a successful ADR issue. And it does not stop there. There is more excitement in store from the company. A 67% growth in sales and 218% growth in bottomline is no mean achievment! A successful integration with Cheminor and superb all round performance has helped the company catapult its size from less than US$ 100 m couple of years back to more than US$ 300 m (Rs 1.5 bn) in the current year.
Operating Profit (EBDIT)
Operating Profit Margin (%)
Profit before Tax
Tax Expense/ (Benefit)
Profit after Tax/(Loss)
Net profit margin (%)
No. of Shares (eoy) (m)
Fully Diluted Earnings per share*
P/E (at current price)
The year has also seen a marked shift in revenue mix of the company. Generics business which started with modest sales in 1QFY02 ended the year with 26% of the company's turnover. This was mainly fuelled by fluoxetine 40 mg capsules contributing around 21% to the total turnover of the company i.e. Rs 3,286 m (US$ 67 m), surpassing our expectations. It may be recalled that Dr. Reddy's received a para IV certifications (which entitles the company to have 180 days generic marketing exclusivity) for fluoxetine in the Aug' 01. The 180-day marketing exclusivity for Fluoxetine expired on January 29' 02. Excluding fluxoetine, total revenues grew by 31% during the year.
While the generics business of the company is targeted at developed markets, where patent laws are strong, the international branded formulations market addresses other geographies. Even this segment of the company recorded a strong growth of 56% on the back of spurt in formulations exports to Russian markets, which recorded a 100% growth during the year. Apart from Russian markets, China and Brazil are emerging strong markets for the company in this segment. The Chinese product lineup is strong with 9 product approvals already inplace and 12 more in the pipeline.
In the domestic formulations business, sales recorded growth of 11%. The growth in domestic formulations business was driven by new product introductions and strong performance of the company's brands viz. Nise, Omez and Stamlo. As per latest rankings, Dr. Reddy has been ranked 6th in the domestic pharma market. The company also acquired six dental brands from Group Pharmaceuticals, with sales of Rs 160 m in the domestic market.
On the research front, DRF-2725 (diabetes molecule) licensed to Novo Nordisk is in advanced stages of Phase III clinical trials and is advancing fast before it enters commercialisation stage. This is the first of its kind of insulin sensitiser and its entry into commercial stage could trigger a huge royalty for the company. Interestingly, the company also received Rs 100 m on account for contract research services during the year. The R&D expense of the company has gone up considerably to 7% of its sales.
At the current price of Rs 965, the stock is trading at 16x its FY02 earnings. Export growth story remains in place with the company penetrating further into new geographies and generics monentum maintaining pace. However, one should bear in mind that the performance in the current year, to a large extent was attributable to non-recurring one time revenues of fluoxetine exports, which contributed almost 21% of the company's sales. Having said that, the performance of the company even excluding this one time revenues has been exceeding well. It is clear that the company is making major strides in R&D, which are expected to bear rich dividends going forward. Though failure cannot be ruled out, there could be a huge opportunity if the insulin sensitiser enters commercialisation. The company is further armed with huge cash reserves to make further investments in R&D and creating/ acquiring marketing infrastructure for the export market.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India. Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407